Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan

Journal of Controlled Release - Tập 153 - Trang 288-296 - 2011
Kareen Riviere1, Heidi M. Kieler-Ferguson1, Katherine Jerger1, Francis C. Szoka1
1Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California, San Francisco, California 94143-0912, USA

Tài liệu tham khảo

Azrak, 2004, Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts, Clin. Cancer Res., 10, 1121, 10.1158/1078-0432.CCR-0913-3 Fischel, 2001, Ternary combination of irinotecan, fluorouracil–folinic acid and oxaliplatin: results on human colon cancer cell lines, Br. J. Cancer, 84, 579, 10.1054/bjoc.2000.1600 Grivicich, 2005, The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells, Chemotherapy, 51, 93, 10.1159/000085617 Peters, 2000, Basis for effective combination cancer chemotherapy with antimetabolites, Pharmacol. Ther., 87, 227, 10.1016/S0163-7258(00)00086-3 Mayer, 2006, Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice, Mol. Cancer Ther., 5, 1854, 10.1158/1535-7163.MCT-06-0118 Tallarida, 2001, Drug synergism: its detection and applications, J. Pharmacol. Exp. Ther., 298, 865 Vaage, 1993, Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes, Int. J. Cancer, 54, 959, 10.1002/ijc.2910540616 Abraham, 2004, In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading, Clin. Cancer Res., 10, 728, 10.1158/1078-0432.CCR-1131-03 Wang, 2005, In vitro cytotoxicity of stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells, Biol. Pharm. Bull., 28, 822, 10.1248/bpb.28.822 Yamashita, 2007, Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts, Neuro Oncol., 9, 20, 10.1215/15228517-2006-016 Krauze, 2007, Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts, Neuro Oncol., 9, 393, 10.1215/15228517-2007-019 Wu, 2007, Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil, J. Pharm. Pharm. Sci., 10, 350 Tardi, 2009, In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy, Leuk. Res., 33, 129, 10.1016/j.leukres.2008.06.028 Tardi, 2009, Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo, Mol. Cancer Ther., 8, 2266, 10.1158/1535-7163.MCT-09-0243 Ramsay, 2005, The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations, Curr. Drug Deliv., 2, 341, 10.2174/156720105774370294 Mayer, 2007, Optimizing combination chemotherapy by controlling drug ratios, Mol. Interv., 7, 216, 10.1124/mi.7.4.8 Bayne, 2009, Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse, J. Pharm. Sci., 98, 2540, 10.1002/jps.21620 Harasym, 2007, Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios, Oncol. Res., 16, 361, 10.3727/000000006783980937 Batist, 2009, Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors, Clin. Cancer Res., 15, 692, 10.1158/1078-0432.CCR-08-0515 Drummond, 2006, Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy, Cancer Res., 66, 3271, 10.1158/0008-5472.CAN-05-4007 Dicko, 2007, Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes, Int. J. Pharm., 337, 219, 10.1016/j.ijpharm.2007.01.004 Tardi, 2007, Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo, Biochim. Biophys. Acta, 1768, 678, 10.1016/j.bbamem.2006.11.014 Kaiser, 2003, 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties, Int. J. Pharm., 256, 123, 10.1016/S0378-5173(03)00069-3 Heath, 1985, 5-Fluoroorotate: a new liposome-dependent cytotoxic agent, FEBS Lett., 187, 73, 10.1016/0014-5793(85)81217-5 Heath, 2005, Methodology and experimental design for the study of liposome-dependent drugs, Methods Enzymol., 391, 186, 10.1016/S0076-6879(05)91011-2 Heath, 1987, Antiproliferative and anticontractile effects of liposome encapsulated fluoroorotate, Invest. Ophthalmol. Vis. Sci., 28, 1365 Heidelberger, 1958, Studies on fluorinated pyrimidines. II. Effects on transplanted tumors, Cancer Res., 18, 305 Skehan, 1990, New colorimetric cytotoxicity assay for anticancer-drug screening, J. Natl Cancer Inst., 82, 1107, 10.1093/jnci/82.13.1107 Chou, 1984, Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv. Enzyme Regul., 22, 27, 10.1016/0065-2571(84)90007-4 Chou, 2006, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol. Rev., 58, 621, 10.1124/pr.58.3.10 Clerc, 1995, Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients, Biochim. Biophys. Acta, 1240, 257, 10.1016/0005-2736(95)00214-6 Bono, 1964, Methyl-5-Fluoroorotate: synthesis and comparison with 5-fluoroorotic acid with respect to biological activity and cell entry, Cancer Res., 24, 513 Straubinger, 1988, Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes, Cancer Res., 48, 5237 Abraham, 2005, The liposomal formulation of doxorubicin, Methods Enzymol., 391, 71, 10.1016/S0076-6879(05)91004-5 Zucker, 2009, Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties, J. Control. Release, 139, 73, 10.1016/j.jconrel.2009.05.036 Dicko, 2008, Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes, Pharm. Res., 25, 1702, 10.1007/s11095-008-9561-z Mayhew, 1979, Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes, Cancer Treat. Rep., 63, 1923 Fox, 2009, Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer–camptothecin conjugates, Mol. Pharm., 6, 1562, 10.1021/mp9001206